Shanghai Saibaiman Biotechnology

Shanghai Saibaiman Biotechnology is a Chinese biopharmaceutical company focused on the development of innovative cell therapies for cancer and autoimmune diseases. The company specializes in next-generation Chimeric Antigen Receptor T-cell (CAR-T) technologies, targeting novel antigens such as CD79a and CD79b to overcome limitations of current CD19-targeted therapies. Their research emphasizes improving the persistence and efficacy of cell therapies in treating B-cell malignancies and refractory autoimmune conditions. Saibaiman operates primarily out of Shanghai, leveraging advanced genetic engineering to build a robust pipeline of hematological and solid tumor candidates.